CRISPR Therapeutics AG — Director's Dealing 2021

Mar 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-03-23

Reporting Person: Klein Lawrence Otto (CBO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-23	Common Shares	M	12000	$44.67	Acquired	25050	Direct
2021-03-23	Common Shares	M	22000	$51.49	Acquired	47050	Direct
2021-03-23	Common Shares	M	10000	$29.87	Acquired	57050	Direct
2021-03-23	Common Shares	M	20000	$40.87	Acquired	77050	Direct
2021-03-23	Common Shares	M	12000	$14.43	Acquired	89050	Direct
2021-03-23	Common Shares	M	12000	$17.66	Acquired	101050	Direct
2021-03-23	Common Shares	S	88000	$128.20	Disposed	13050	Direct
2021-03-23	Common Shares	S	12000	$126.97	Disposed	1050	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-23	Stock Option (Right to Buy)	$14.43	M	12000	Disposed	2027-06-14	Common Shares (12000)	Direct
2021-03-23	Stock Option (Right to Buy)	$17.66	M	12000	Disposed	2027-11-14	Common Shares (12000)	Direct
2021-03-23	Stock Option (Right to Buy)	$51.49	M	22000	Disposed	2028-03-06	Common Shares (22000)	Direct
2021-03-23	Stock Option (Right to Buy)	$29.87	M	10000	Disposed	2029-01-01	Common Shares (10000)	Direct
2021-03-23	Stock Option (Right to Buy)	$40.87	M	20000	Disposed	2029-03-05	Common Shares (20000)	Direct
2021-03-23	Stock Option (Right to Buy)	$44.67	M	12000	Disposed	2030-03-10	Common Shares (12000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.78 to $132.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $130.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017.

F5: 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on December 15, 2017.

F6: 100% of the shares shall vest in 48 equal monthly installments on the seventh day of each month, with the first vesting event on April 7, 2018.

F7: 25% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month.

F8: This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019.

F9: This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.